Background
MOTS-c was identified in 2015 as part of a broader recognition that mitochondrial DNA encodes small bioactive peptides. These mitochondrial-derived peptides (MDPs) — including humanin and MOTS-c — expanded the understanding of mitochondria from energy-producing organelles to endocrine-like signaling hubs. Since its discovery, MOTS-c has been studied in preclinical models of obesity, insulin resistance, exercise physiology, and aging. Human research has been limited to observational studies measuring circulating peptide levels; controlled therapeutic trials had not been published as of mid-2024.
Evidence snapshot
Discovery and preclinical studies: MOTS-c was first described in 2015 as a short peptide encoded within the mitochondrial 12S rRNA locus. In rodent and cell-culture models, MOTS-c treatment improved glucose tolerance, increased insulin sensitivity, reduced weight gain on high-fat diets, and altered skeletal muscle metabolism via AMPK activation and modulation of nuclear gene expression.
Human and clinical evidence: Human data are sparse. Observational studies report correlations between circulating MOTS-c levels and metabolic markers (insulin resistance, BMI) in small cohorts, but no randomized controlled trials in humans have been published as of mid-2024. Safety, pharmacokinetics, and effective dosing in humans remain unestablished.
Mechanistic uncertainty and limitations: Positive findings come from rodent models or in vitro systems using synthetic peptide. Pharmacokinetics, tissue distribution, and long-term effects in humans are unknown. Translation from mouse doses to human-equivalent dosing is theoretical. Controlled human trials are necessary before any clinical use can be considered.
Bioavailability and pharmacokinetics
Virtually all MOTS-c pharmacokinetic data come from parenteral dosing in animals (intraperitoneal or intravenous). Oral bioavailability in humans has not been demonstrated; peptide stability is limited by gastrointestinal proteolysis. In animal models, skeletal muscle and metabolic tissues respond to administered peptide, but systematic human pharmacokinetic studies are absent. Formulation strategies such as pegylation and lipid-based carriers are under investigation in preclinical settings to improve stability and tissue exposure.
Populations studied
Preclinical research has used young mice, diet-induced obese rodents, aged mice, and cell-culture models. Human research to date is observational and cross-sectional, measuring circulating MOTS-c concentrations in small cohorts with obesity, type 2 diabetes, or following acute exercise. No large randomized trials exist. Safety and efficacy in pregnant women, children, older adults with comorbidities, or people on polypharmacy are entirely unknown.
Long-term safety and regulatory status
Long-term safety data in animals are limited, and human safety data are absent. MOTS-c is not an approved drug or regulated dietary supplement with established safety and efficacy. In most jurisdictions, experimental peptide use falls under investigational medicinal product or research-use-only frameworks. Chronic modulation of AMPK and related metabolic signaling could have unintended consequences; this has not been evaluated in any long-term human study.
Research-grade vs. commercial products
Some vendors sell synthetic MOTS-c, but these products are typically intended for laboratory research and are not manufactured or regulated for human administration. Research-grade peptide suppliers provide certificates of analysis for laboratory use only. Clinical-grade manufacturing (GMP) and formal regulatory approval would be required for legitimate therapeutic application. Consumers and clinicians should exercise significant caution regarding off-label or self-administered peptide products of unknown quality.
Compound variations
Synthetic full-length MOTS-c peptide
The canonical 16-amino acid MOTS-c sequence used in most preclinical studies, typically delivered by injection in animal experiments.
Common use case
Research use in cell and animal models; mechanistic studies.
Dosage note
Animal studies commonly use 0.5–5 mg/kg/day via injection. Human-equivalent dosing is theoretical and untested (see dosage principles).
Stabilized MOTS-c analogs
Chemically modified variants (e.g., D-amino acid substitutions, pegylation) designed to increase half-life and potentially oral bioavailability in research settings.
Common use case
Preclinical pharmacokinetic or chronic dosing studies requiring extended peptide exposure.
Dosage note
Effective doses depend on the specific modification. Modified analogs may allow lower or less frequent dosing in animal models but require independent safety and efficacy testing.
Delivery forms (injectable, nanoparticle, oral formulations)
Investigational delivery systems — including nanoparticle carriers and lipid formulations — aimed at improving peptide stability and tissue targeting.
Common use case
Preclinical delivery optimization studies to reduce proteolytic degradation and improve tissue uptake.
Dosage note
Route of administration substantially affects bioavailability. Most robust metabolic effects in animals used injectable routes; oral formulation work is in early preclinical stages.
Dosage and best practices
Dosage principles
- Preclinical mouse studies typically use intraperitoneal injections of approximately 5 mg/kg/day. Applying standard body surface area scaling (Km: mouse = 3, human = 37), this converts to a human-equivalent dose of roughly 0.4 mg/kg/day (~28 mg/day for a 70 kg person). This conversion is a rough guide only and has not been validated clinically (Nair & Jacob, 2016).
- Some animal studies report activity at lower doses (0.5–2 mg/kg in rodents) depending on route and formulation. Dose-response relationships have not been characterized in humans.
- No clinically validated oral dosing regimen exists. Most experimental administrations in animals were parenteral (injectable). Oral bioavailability in humans is unproven, and peptide stability is limited by proteolysis.
Best practices
- Treat MOTS-c as a research-grade compound. Commercially available products vary substantially in purity and are not subject to regulatory oversight for human use.
- Do not self-administer injectable peptides. Any participation in research involving MOTS-c should occur through a supervised clinical trial with established safety monitoring protocols.
- If participating in monitored research, track objective metabolic measures (fasting glucose, HOMA-IR, body composition) alongside any subjective changes in energy or recovery.
Literature and references
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Cell metabolism • 2015
A simple practice guide for dose conversion between animals and humans
Journal of Basic and Clinical Pharmacy • 2016
Standard body surface area (Km) conversion factors for estimating human-equivalent doses from animal data; provides the basis for contextualizing reported animal MOTS-c doses.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Nature communications • 2021
Demonstrated that MOTS-c is released into circulation during exercise and that exogenous MOTS-c improves physical performance and muscle homeostasis in aged mice, linking the peptide to exercise physiology and aging.
Common questions
Is MOTS-c available as an over-the-counter supplement?
MOTS-c is not an approved dietary ingredient. Some vendors sell synthetic MOTS-c peptides, but these are research materials and are not regulated for human use. Quality and purity are not guaranteed.
Are there human clinical trials showing benefit?
As of mid-2024, no randomized controlled trials have demonstrated clinical benefit of MOTS-c in humans. Evidence is primarily preclinical (rodent models and cell studies) and observational.
Can I take MOTS-c with diabetes medications?
MOTS-c modulates insulin sensitivity in preclinical models and could interact with glucose-lowering medications. Combining them without medical supervision and frequent glucose monitoring is not advisable.
How soon would effects appear if MOTS-c were effective?
In animal studies, metabolic and molecular changes were measurable within days to weeks of treatment. Human timelines are unknown. Any experimental use should include objective monitoring over weeks to months.
Is MOTS-c safe long term?
Long-term safety in humans has not been established. Animal data are limited in scope and cannot reliably predict chronic effects in people. Clinical oversight is essential for any prolonged exposure.